Abstract
The Recruitment and Retention for Alzheimer's Disease Diversity in the Alzheimer's Disease Sequencing Project (READD-ADSP) aims to recruit 5000 African participants (Alzheimer's disease [AD] and cognitively unimpaired controls) to generate genomic and biomarker data to better characterize AD neurobiology in Africa from countries that constitute the African Dementia Consortium (AfDC). Blood samples from study participants are separated into fractions and transported to the African Coordinating Centre (ACC: Ibadan, Nigeria), where DNA extraction and long-term biospecimen storage are carried out. Plasma and DNA aliquots are shipped to the John P. Hussman Institute for Human Genomics, University of Miami (HIHG-UM, Miami, USA) for genotyping, whole genome sequencing, and biomarker analysis. Innovative solutions were devised to mitigate challenges encountered so far. Our biobanking experience in a low-resource setting demonstrates the feasibility of establishing a successful African biobanking network, as an important infrastructure to support Alzheimer's disease and related dementias research in Africa. HIGHLIGHTS: Biobanking is gaining grounds in Africa in studies related to neurological disorders. The Recruitment and Retention for Alzheimer's Disease Diversity in the Alzheimer's Disease Sequencing Project (READD-ADSP) biobanking network is a new initiative to enhance infrastructure for Alzheimer's disease and related dementias (ADRD) research in Africa through the African Dementia Consortium. The processes of the stepwise creation and development of the READD-ADSP biobanking network have been guided by global best practices and regulatory standards. Challenges were encountered in the process of establishing the READD-ADSP biobank, and home-grown solutions were developed to mitigate the challenges. The READD-ADSP biobanking experience offers lessons to researchers in low-resource settings on how collaborative efforts between the global north and global south enhance cutting-edge team science to tackle ageing-associated brain disorders in low- and middle-income countries.